Sure. So on the EU and CHMP, so as we've shared previously, in the EU adopted initially a negative opinion. We strongly disagree with that opinion. And I think the basis for that is we are in a randomized placebo-controlled study, met our prespecified primary outcome, showing a slowing in the rate of progression on the ALSFRS-R. We've also observed a difference on overall survival. And that data, of course, led to our approval, but there are full U.S. FDA approval and our approval with conditions in Health Canada. So we believe we have a data package that should, in our view, support approval. But of course, ultimately, this is up to CHMP.
So we submitted for reexamination. That's roughly a 4-month process, under which 2 new repertories are assigned and review the application. We submitted that shortly after we got the negative opinion. So you can expect that near the end of this year, we'll hear back regarding that opinion.
So we submitted for reexamination. That's roughly a 4-month process, under which 2 new repertories are assigned and review the application. We submitted that shortly after we got the negative opinion. So you can expect that near the end of this year, we'll hear back regarding that opinion.

